Author(s): Kim SM, Lee KM, Jong YH, Park KS, Yang JH, et al.
Background: Many patients with amyotrophic lateral sclerosis (ALS) with cognitive impairment have fronto-temporal dysfunction. Whereas in some patients with ALS the fronto-temporal dysfunction is undoubtedly due to the degenerative process associated with the disease, in others dysfunction cannot be accounted for by an irreversible degenerative process alone, as it also appears to involve a reversible process. We hypothesised that reduced vital capacity can be a key contributor to the fronto-temporal dysfunction observed in patients with ALS.
Objective: To investigate the association between fronto-temporal dysfunction and reduced vital capacity in ALS.
Methods: 16 consecutive patients who conformed to a diagnosis of definite or probable ALS (El escorial criteria) were grouped by vital capacity, and their clinical characteristics and cognitive functions, including disease duration, attention, executive function and memory, were measured.
Results: Patients with a reduced vital capacity performed significantly poorer in memory retention (p = 0.028), retrieval efficacy (p = 0.003), spoken verbal fluency (p = 0.03) and spoken verbal fluency indexes (p = 0.016) than those with a normal vital capacity.
Conclusion: The fronto-temporal dysfunction in ALS might be attributable to potentially reversible secondary effects associated with reduced vital capacity, as well as to the primary degenerative process.
Referred From: https://jnnp.bmj.com/lookup/doi/10.1136/jnnp.2006.111195
Author(s): Lattante S, Conte A, Zollino M, Luigetti M, Del Grande A, et al.
Author(s): Sedda A
Author(s): Strong MJ, Abrahams S, Goldstein LH, Wooley S, Mclaughlin P, et al.
Author(s): Chiò A, Battistini S, Calvo A, Caponnetto C, Conforti FL, et al.
Author(s): Sabatelli M, Marangi G, Conte A, Tasca G, Zollino M, et al.
Author(s): Lattante S, Pomponi MG, Conte A, Marangi G, Bisogni G, et al.
Author(s): McCullagh S, Moore M, Gawel M, Feinstein A
Author(s): Agosta F, Al-Chalabi A, Filippi M, Hairdman O, Kaji R, et al.
Author(s): Murphy J, Ahmed F, Lomen-Hoert C
Author(s): Pagnini F, Zachary S (Ed)
Author(s): Goldstein LH, Abrahams S
Author(s): Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, et al.
Author(s): Robinson KM, Lacey SC, Grugan P, Glosser G, Grossman M, et al.
Author(s): Grossman AB, Bonnie EL, Bradley WG
Author(s): Lulè D, Paulì S, Altinas E, Singer U, Mèrk T, et al.
Author(s): Brown WA, Mueller PS
Author(s): Houpt JL, Gould BS, Norris FHJr
Author(s): Peters PK, Swenson WM, Mulder DW
Author(s): Poletti B, Carelli L, Lafronza A, Solca F, Faini A, et al.
Author(s): McElhiney MC, Rabkin JC, Gordon PH, Goetz R, Mitsumoto H
Author(s): Talbot K, Ansorge O
Author(s): Girardi A, MacPherson SE, Abrahams S
Author(s): Lillo P, Savage S, Mioshui E, Kiernan MC, Hodges JR
Author(s): Frances A
Author(s): Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, et al.
Author(s): Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, et al.
Author(s): Benaim C, Desnuelle C, Fourniere-Mehouas M
Author(s): ALS CNTF Treatment Study (ACTS) Phase I-II Study Group
Author(s): Cedarbaum JM, Stambler N
Author(s): Poletti B, Solca F, Carelli L, Madotto F, Lafronza A, et al.
Author(s): Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, et al.